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Abstract
The Vimentin gene plays a pivotal role in epithelial-to-mesenchymal transition and is known to be
overexpressed in the prognostically poor basal-like breast cancer subtype. Recent studies have
reported Vimentin DNA methylation in association with poor clinical outcomes in other solid
tumors, but not in breast cancer. We therefore quantified Vimentin DNA methylation using
MALDI-TOF mass spectrometry in breast tumors and matched normal pairs in association with
gene expression and survival in a hospital-based study of breast cancer patients. Gene expression
data via qRT-PCR in cell lines and oligomicroarray data from breast tissues were correlated with
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percent methylation in the Vimentin promoter. A threshold of 20 percent average methylation
compared with matched normal pairs was set for bivariate and multivariate tests of association
between methylation and tumor subtype, tumor histopathology, and survival. Vimentin was
differentially methylated in luminal breast cancer cell lines, and in luminal A, luminal B, and
HER2-enriched breast tumor subtypes, but was rare in basal-like cell lines and tumors. Increased
methylation was strongly correlated with decreased mRNA expression in cell lines, and had a
moderate inverse correlation in breast tumors. Vimentin methylation predicted poor overall
survival independent of race, subtype, stage, nodal status, or metastatic disease and holds promise
as a new prognostic biomarker for breast cancer patients.
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Introduction/background
The Vimentin gene encodes an intermediate filament protein reported to have varied roles in
cytoskeletal architecture [13, 17, 20], immune response [21], and in stabilization of collagen
mRNAs [1]. Given these multiple functions, Vimentin is considered to have a pivotal role in
epithelial-to-mesenchymal transition (EMT), including upregulation of other EMT
associated genes, adaptive responses to wound healing, and pathological responses during
cell invasion and metastasis [11]. In breast cancer, Vimentin expression is upregulated
during EMT, and is highly expressed in the prognostically poor basal-like subtype of breast
tumors [17, 35, 36, 39].
Although upregulation of Vimentin expression during EMT has been well characterized in
breast cancer, only one study to our knowledge has reported epigenetic changes in Vimentin
derived from breast tumors [8]. Recent studies have explored epigenetic changes in
Vimentin in general, with data showing differential Vimentin DNA methylation in other
solid tumors such as colorectal, gastric, cervical, bladder, and pancreatic cancer [2, 4, 10, 12,
14, 15, 23, 37, 38].
We therefore sought to quantify Vimentin methylation in N = 154 samples using the
SEQUENOM® mass spectrometry platform in breast cell lines, breast tumors, and matched
normal tissue, and to test for associations of methylation with gene expression, molecular
subtypes, and clinical outcomes. Given the poor prognosis of breast cancers having elevated
Vimentin expression, our central hypothesis was that if Vimentin methylation was correlated
with decreased gene expression, then increased methylation would be associated with better
survival. We found high levels of Vimentin methylation negatively correlated with gene
expression only in the HER2+ and ER+ “luminal”-like cell lines. This pattern persisted in
breast tumors, with elevated methylation in the HER2-enriched luminal A, and the HER2-
enriched luminal B subtypes, while extremely low-to-nil methylation was found in 91 % of
basal-like tumors. Importantly, Vimentin methylation strongly predicts poor overall survival
(OS) independent of race, subtype, stage, nodal status, or metastatic disease.
Methods
Cell culture and molecular subtype assignments
All 14 cell lines were grown at 37 °C and 5 %carbon dioxide. MCF-7, ZR-75-1, HCC1937,
T47D, SUM149PT, SUM159PT, SUM102, MDA-MB-231, SKBR3, and MDAMB-468
were obtained from Aster and or the American Tissue Culture Collection (Manassas,
Virginia). MCF-7, ZR-75-1, HCC1937, and T47D were cultured in PRMI medium with 10
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% fetal bovine serum and penicillin and streptomycin solution (500ug/ml). SUM149PT and
SUM159PT were cultured in HAM’s F-12 medium with 5 % fetal bovine serum, insulin (5
ug/ml), Hydrocortisone (1 ug/ml), Amphotericin B (0.5 ug/ml), and Gentamycin (5 ug/ml).
SUM102 and ME16C were cultured in HuMeC with 0.5 % BPE, 1 % HuMeC supplement,
and Gentamycin (5 ug/ml). MDA-MB-231, SKBR3, and MDA-MB-468 were cultured in
DMEM, McCoy’s 5A, and L-15, respectively, each with 10 % fetal bovine serum and
penicillin and streptomycin solution (500 ug/ml). MCFDCIS, MCF10AT1, and
MCF10DCIS were cultured in DMEM/F-12, with 20 ng/ml epidermal growth factor, 0.5 ug/
ml hydrocortisone, 0.1 ug/mL cholera toxin, 10 ug/ml insulin and penicillin and
streptomycin solution (500 ug/ml).
Cell lines were authenticated by gene expression, and all cell lines tested negative for
Mycoplasma contamination using the MycoProbe Mycoplasma detection assay cat. no.
UL001B (R&D Systems, Minneapolis, MN).
Cell line categories by hormone/growth receptor status and molecular
subtype—The seven estrogen receptor (ER) and progesterone receptor (PR) negative cell
lines; HCC1937, SUM102, SUM149PT, MDA-MB-468, ME16C, SUM159PT, and MDA-
MB-231 were collectively grouped as “hormone receptor negative” (HR−), and the HER2 +
SKBR3 and three ER+ cell lines (T47D, MCF-7, and ZR-75) were grouped as “hormone
receptor positive” (HR+). The basal-like and luminal molecular subtype classifications of
the cell lines used in this study were based on previous studies using hierarchical clustering
of oligoarray data from approximately 50 breast cancer cell lines [24, 29]. The classification
used by Neve et al., (2006) distinguished basal A from basal B cell lines. For simplicity,
however, we used the broader designation of “basal-like” to encompass both basal A and
basal B cell lines.
RNA and DNA isolation from cell lines and human tissues
Human breast tumor and paired normal tissues were collected from fresh frozen samples
following Biomedical Institutional Review Board approval through the UNC Office of
Human Research Ethics. All breast tumors used in this study were selected to have greater
than 50 % tumor cells by pathology/histology analysis, and on average had 70 % tumor
epithelium. Depending on sample type, DNA extraction was carried out with either the
Qiagen Pure-gene® Core Kit A or the Qiagen DNAeasy® Blood and Tissue Kit (Qiagen,
Germantown, MD, USA). The Qiagen RNeasy® Mini Kit RNA was used to extract RNA
before DNA isolation and served as a template for both oligo array and qRT-PCR
experiments. For qRT-PCR, RNA was reverse transcribed using miScript Reverse
Transcription Kit (Qiagen, cat. no. 218061), and the product was treated with RNAse-free
DNase I.
Previously obtained DNA oligoarray expression data in breast tumor and matched normal
tissues
Methylation studies were carried out on DNAs extracted from previously analyzed breast
tumors and matched normal breast tissues that had already been profiled for gene expression
using DNA oligonucleotide arrays (Agilent Technologies, Santa Clara, CA, USA) [9].
Pending publication, all microarray data are temporarily available at http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=dvqrtwaeewcyuns&acc=GSE35629, which
are deposited in the Gene Expression Omnibus (GEO) under the accession number
GSE35629. Array data for individual breast tumors are found in hypertext at the bottom of
the above URL. Molecular subtypes of breast tumors were assigned using the PAM50
algorithm as previously described [26]. In total, five classifications were assigned that
included: Luminal A, Luminal B, Basal-like, HER2-enriched, and Normal-Breast-Like. The
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normalized log2 ratios (Cy5 sample/Cy3 control) of Vimentin probe P161190 were median-
centered before generating relative gene expression values. These values were used to
correlate gene expression with percent methylation values for the CpG units interrogated in
the Vimentin amplicon by means of mass spectrometry (Table 1).
Patient clinical and demographic data, molecular subtypes for each tumor and matched
normal pair, and GEO accession numbers are listed in Supplemental File 1. There were n =
83 tumors and n = 57 matched tumor normal pairs (N = 140 total breast samples). In brief,
this cohort was 63 % white, 29 % black, and 8 % other with an average breast cancer onset
age of 56 years. Three of N = 83 breast cancer cases were male. Distribution of molecular
subtypes were as follows: 29 % Luminal A, 28 % Luminal B, 27 % Basal-like, 12 %HER2
enriched, and 2 %Normal-like. The two Normal-like tumors identified with the PAM50
predictor were subsequently excluded from methylation scatter plots, gene expression
correlation, and survival analyses. The mean and median years of follow-up were 5.5 and
5.2 years, respectively; over a third of the breast cancer cases had between 7 and 15 years of
follow-up.
qRT-PCR gene expression analysis in breast cell lines
Gene expression in breast cell lines was quantified using qRT-PCR on a 7500 Real-Time
PCR Platform (Applied Biosystems, Foster City, CA). Relative cDNA quantity was
measured using pre-designed ABI TaqMAN probes and primers for Vimentin (VIM-
Hs00185584_m1) and GAPDH (GAPDH-Hs02758991_g1) as the endogenous expression
control (Applied Biosystems, Foster City, CA.) Cell line cDNAs were examined in
triplicate, with qRT-PCR cycling as follows: 50 °C for 2 min, denaturation at 95 °C for 10
min, followed by 40 cycles of 95 °C for 15 s, and 60 °C annealing for 1 min.
Positive and negative DNA methylation controls
Artificially synthesized methylation controls were made as previously described [40]. In
brief, 2 ug of human sperm DNA (unmethylated control) or 2 ug MDA-MB-231 DNA were
treated in separate 20-µl reaction volumes of SSsI CpG methyltransferase (New England
Biolabs, Beverly, MA) for 1.5 h at 37 °C before sodium bisulfite (NaBi) conversion. Percent
mixtures were made of unmethylated and artificially methylated (positive controls) ranging
from 0 to 100 % and quantified for both Vimentin and GAPDH amplicons using
MassARRAY (See Supplementary Table 3). Non-NaBi-converted DNAs were used as
negative template controls.
Sodium bisulfite conversion of DNA
The EZ DNA Methylation-Direct Kit (Zymo Research, Irvine, CA, USA) was used to
sodium bisulfite convert genomic DNA extracted from cell lines, methylated controls, and
breast tissue. As per protocol, the 5.5 h C → U conversion reaction (all U’s are converted to
T during PCR) was performed on a thermocycler at 95 °C for 30 s and 50 °C for 15 min for
20 cycles.
Quantifying Vimentin methylation using mass spectrometry
Percent Vimentin methylation was quantified using mass spectrometry with the
EpiTYPER® T complete reagent kit. The kit included reagents for PCR, transcription and t-
cleavage reactions, Clean Resin, and 10 silicon matrix SpectroCHIPs® (with a capacity of
384 samples per chip) to perform the mass spectrometry. The SEQUENOM Epi-TYPER®
methylation assay has been validated in numerous studies and previously described in detail
[3, 6, 7, 31, 41]. We first custom designed the primers for an amplicon that included the core
Vimentin promoter (Fig. 1), as predicted by http://linux1.softberry.com/berry.phtml?
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Promoter/ PCR was then carried out on 5–10 ng of sodium bisulfite-converted sample DNA
using NaBi conversion-specific primers with lower case letters representing the T7 tag
sequence (Forward–aggaagagagGAGAGTGGTAGAGGATTGGATTT and Reverse–
cagtaatacgactcactatagggagaaggctCTTTTTCAACACCCCAAAATAAAC) in a 5-µl reaction
volume under the following conditions: 95 °C for 2 min, with a series of touch down
reactions for two cycles at 95 °C for 30 s, 60 °C for 30 s, 72 °C for 1 min; two cycles each
with 59, 58, and 57 °C annealing, respectively; followed by 40 cycles at 56 °C annealing.
Final extension was at 72 °C for 5 min. Unincorporated dNTPs were dephosphorylated with
shrimp alkaline phosphatase before adding 2 µl of the reaction as a template for the in vitro
transcription reaction as per the EpiTYPER protocol. RNase-A was added in the final T
cleavage reaction that rendered unmethylated and methylated CG-containing fragments.
Methylated versus unmethylated CGs peaks are easily identified because of a 16 Dalton
mass shift between the two peaks. The EpiTYPER® software then calculates the relative
ratio of methylated to unmethylated CGs as percent methylation within a 5 % methylation
confidence margin [3, 6, 32]. After the cleavage reaction, resulting fragments may contain
more than one CG dinucleotide, and are therefore referred to as “CpG units.” In such cases,
percent methylation based on the ratio of methylated to unmethylated fragments is
calculated as previously described [3]. Because the Mass ARRAY platform allows accurate
percent methylation calculations between 1,000 and 8,000 Dalton windows, values for CG-
containing fragments falling near or outside this mass window cannot be reliably quantified
and are assigned an “N/A.” For example, there are no data for CpG # 9, 11, 12, and 13 of the
Vimentin amplicons because their cleavage fragments fell outside the EpiTYPER mass
detection window. In addition, CpG #10 and 15 were excluded from the statistical analysis
because they trended with similar methylation values across all sample types, including
matched normal tissues. All analyses in this study were therefore performed on CpG
sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 16, and 17 as shown in Fig. 2a. Percent methylation
data for both GAPDH and Vimentin in positive and negative methylation controls, and in
breast cancer cell lines, are provided in Supplemental File 3. Methylation data for each
tumor and matched normal pair are provided in Supplemental File 2. Because the magnitude
of methylation differs between sample types, the terms “hypermethylation” and
“hypomethylation” throughout this article broadly refer to any sample with >20 and <20 %
Vimentin methylation, respectively.
Statistical analyses
Average linkage hierarchical clustering of Vimentin methylation in cell lines (Fig. 2a) was
performed and displayed using MeV (version 4.8.1) of the TM4 software suite [33]. The
Student’s t test was used to determine the difference between log-relative gene expressions
in cell lines (Fig. 2c), as measured using an ABI real-time platform. In addition, gene
expression differences were verified using the more conservative Wilcoxon Rank test
(Mann–Whitney U). Relative gene expression in tumors was measured by normalized log2
ratios (Cy5 sample/Cy3 control) of the Agilent Vimentin oligoarray probe P161190. The
Pearson r statistic was used to correlate relative gene expression and percent methylation in
both tumors (Table 1) and cell lines. Differences in mean percent methylation between
molecular breast cancer subtypes (Fig. 3c) was assessed using analysis of variance
(ANOVA). Cox proportional hazards models (Table 2) and Kaplan–Meier survival curves
(Fig. 4a–f) were generated in SAS (SAS institute, Inc., Cary, NC), and the survival curves
were compared by the log-rank statistical test. Reported p values are two-sided. A complete
description of the hazard modeling and model selection is provided in Supplemental File 4.
All other statistical analyses were performed in R (http://www.R-project.org), unless
otherwise noted.
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Vimentin methylation in breast cell lines
We designed bisulfite conversion-specific primers to the Vimentin gene promoter located 5’
of the ATG start site. CpG sequences in the 282-bp amplicon spanning from −413 to −132
bp from the translational start site (TSS) were interrogated based on NCBI build 36/hg 19
(Fig. 1). Percent Vimentin methylation for CpG sequences interrogated in 14 breast cancer
cell lines are shown in Fig. 2a and in Supplemental File 3.
Previous studies have characterized breast tumor cell lines and hTERT immortalized cells
from breast tissues as having intrinsic molecular subtypes by means of DNA microarray
analysis [22, 24, 29]. The basal-like and luminal subtype characterizations previously
described mirrored hormone receptor (HR) status and were applied to the cell lines used in
this study [24]. The luminal, HR+ breast tumor cell lines (ZR75, T47D, and MCF7) were
hypermethylated for CpGs 1–17, as was the luminal, HER2+ cell line, SKBR3. In contrast,
the remaining basal-like HR− cell lines (SUM159PT, ME16C, SUM102, SUM149PT,
HCC1937, MDA-MB-468, MDA-MB-231, MCF10A, MCF10AT1, and MCF10DCIS) were
hypomethylated across the Vimentin amplicon (Fig. 2a).
Correlations with vimentin methylation and gene expression in cell lines
Percent methylation per CpG sequence was compared to relative expression of Vimentin
mRNA in cell lines using qRT-PCR. As seen in Fig. 2b, the Vimentin mRNA product band
is boldly visible in the basal, HR− cell lines and weak or absent in the luminal, HR+ cell
lines (lanes 1–4). Both linear and exponential regressions were applied to individual CpG
sites as well as to weighted and unweighted averages across the Vimentin amplicon.
Exponential regression fit the un-weighted data with a Pearson correlation value of −0.92 (p
< 0.0001). CpG site 17 was the most inversely correlated with gene expression at −0.96 (p <
0.00001), while the remaining CpG sites had correlations ranging from −0.78 to −0.96 (p <
0.01).
A student’s t test was used to compare mean relative quantity (RQ), the differences of
Vimentin expression between the HR+ and HR− groups (Fig. 2c). Hypomethylated HR− cell
lines had significantly higher Vimentin mRNA than hypermethylated HR+ cell lines (t =
10.12; p < 0.00001). In addition, a more statistically conservative non-parametric Mann–
Whitney test was applied because of the potential violation of normality assumptions for
percent methylation values (Fig. 2c). Again, differences in mean gene expression between
the HR− and HR+ cell lines remained significant (U = 32.0; p < 0.01).
Vimentin methylation in breast tumors and matched normal pairs
Molecular subtypes for breast tumors were assigned based on Agilent oligoarray log2 gene
expression values using the PAM50 predictor as previously described [29]. The magnitude
of Vimentin methylation varied according to sample type. Overall, Vimentin methylation
values were higher in luminal cell lines (>50 % average methylation for SKBR3 and >75
%average methylation for the three ER+ cell lines) than those found in breast tumors (>20
% average methylation) and matched normal tissue (~5 % average methylation). The scatter
plot in Fig. 3a shows percent Vimentin methylation distributions per CpG unit for breast
tumors grouped by molecular subtype. Luminal and HER2-enriched (HER2 over-
expressing) subtypes are differentially methylated in comparison with paired normal tissues,
whereas basal-like tumors are not significantly more methylated than their paired normal
tissues, with the exception of 9830-030619 and UNC01-0318 (Fig. 3b). We measured
methylation in paired tumor normal breast tissues as an indicator of possible field effects
and as a base line reference. As per Fig. 3b, the dynamic range of methylation varied greatly
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in tumors (particularly luminal and HER2 enriched tumors) but was very low in matched
normal pairs taken from the ipsilateral breasts of the tumor samples. Only one matched
pathologically normal breast tissue sample had average methylation of 11 % (Luminal B
normal sample BC00017, Fig. 3b). With the exception of four samples with average
methylation ranging between 6 and 8 %, the remaining normal samples had <5 % average
methylation (Supplemental File 2).
Analysis of variance (ANOVA) results in Fig. 3c show statistically different methylation
values at the CpG#17 site between tumor subtypes (p < 0.0001). Only results for CpG 17 are
shown; however, equally significant differential methylation values were observed for the
other CpG units. For each CpG unit, the median percent methylation of HER2-enriched,
luminal B, or luminal A subtypes is higher than that of basal-like tumors and matched
normal tissues (Fig. 3c). Given the published sensitivity of the Sequenom Epityper
MassARRAY to quantify methylation in biological samples, including from FFPE or
samples with limited cellularity [32, 41], the baseline methylation results we obtained from
matched normal breast tissues enabled us to set relevant methylation thresholds in our
survival analyses.
Correlating vimentin methylation in breast tumors with gene expression
In contrast to cell lines, correlation coefficients in breast tumors were lower, but remained
significant. Table 1 shows inverse correlations ranging from −0.228 to −0.381 (p < 0.03),
which were derived from log2 expression (R/G) of the Vimentin Agilent microarray probe
P161190 versus percent methylation per Vimentin CpG unit. Lower negative correlations
are likely due in part to the increased cellular heterogeneity found within tumors, relative to
much higher cellular homogeneity observed in cell lines. Although correlations in breast
tumors were lower overall, they nevertheless remained statistically significant (Table 1).
Survival analysis: Vimentin methylation in association with clinical factors
Distribution plots of average Vimentin CpG methylation across the amplicon revealed a
threshold of methylation between 15 and 20 % relative to matched normal controls (Fig. 3a,
b). In the light of the significant negative correlation findings with gene expression, we
conservatively chose 20 % Vimentin methylation thresholds to model survival in Cox
proportional hazards bivariate analyses. Figure 4a–d shows Vimentin methylation
significantly predicted OS and recurrence-free survival (RFS) for all tumor subtypes, as well
as in the subset where the basal-like subtypes were removed from the analysis (Fig. 4c, d).
After further parsing the tumor samples by ER status, Vimentin methylation predicted OS in
ER+ but not in ER− tumors (Fig. 4e, f).
In order to test if other confounding predictors of survival explained the Vimentin
methylation finding, we considered other available predictors one at a time in Cox
regression bivariate analyses (Table 2). For predictors with more than two values, e.g.,
molecular subtype, tumor size; and tumor stage, reference values, were assigned to the least
clinically severe category. The p values reported for the other categories within a
multicategory predictor address if the unadjusted hazard rate for the time to death was
different for that category as compared with the reference category.
Predictors with no distinct effects for the survival in the bivariate analysis were not
considered in subsequent multivariate analyses (Supplemental File 4). Multivariate Cox
regression models of the time to death were then tested in combinations of marginally
significant (p < 0.10) predictors from the bivariate analyses: methylation >20 %; female;
luminal B subtype; tumor size 2–5 cm; tumor size >5 cm; nodal status at diagnosis;
metastatic disease at diagnosis; and stage II, stage III, and stage IV breast cancer. Using
Ulirsch et al. Page 7













these ten predictors of time to death, we generated composite models through forward
selection, stepwise selection, and backward elimination, with p = 0.05 as the basis for
removing and retaining variables. All three alternatives generated the same model with the
following predictors as shown in Multivariate model 1A (Table 2). We also repeated the
process for Multivariate Model 1B, except that the three male breast cancer cases were
removed from the analysis. The hazard ratios in Table 2 were based on multivariate model
1B, which show that after controlling for the effects of lymph node status and metastatic
disease on survival, the estimated hazard for females dying from breast cancer is 2.6 times
greater for those with average Vimentin methylation >20 %, as compared to those with <20
% methylation (95 % CI, 1.2–5.3).
Discussion
Vimentin methylation was observed in both luminal cell lines and in luminal and HER2-
enriched molecular tumor subtypes, but infrequent in the basal-like tumors. Overall,
increased methylation was negatively correlated with Vimentin mRNA levels quantified via
qRT-PCR in cell lines and by oligomicroarray in breast tumors. Our results mirror other
tumor studies where Vimentin methylation was also shown to be inversely correlated with
gene expression in cervical cancer [12] and in bladder cancer cell lines [4]. In general,
previous studies showed that Vimentin methylation was differentially methylated in gastric,
cervical, hepatocellular, and colorectal tumor versus normal tissues [12, 14–16, 37] and was
associated with a higher tumor stage and grade in liver cancer [15].
Because previous studies have shown up-regulated Vimentin expression is associated with
EMT, poor prognosis, and the basal-like subtype [18, 26, 29, 39], our strong association
finding of increased Vimentin methylation with markedly decreased survival, particularly
within ER + disease, was counter to our hypothesis and merits further exploration. Breast
cancer is inherently heterogeneous and represents at least two different diseases [27, 28]. At
minimum, therefore, the methylation marks we quantified in the Vimentin promoter are
likely to have a complex etiology that differs between basal and non-basal like tumors.
Nevertheless, there may be several possible contributors to this finding.
First, even in homogenous cell culture, high levels of methylation did not completely silence
expression in the luminal and SKBR3 cell lines (Fig. 2a, b), suggesting the dose–response of
Vimentin methylation may differ between mRNA and protein. We were not able to assess
Vimentin protein because only DNA remained from the previously analyzed tumor and
tumor normal samples for which oligoarray gene expression data were already available.
However, past studies have found Vimentin protein being consistently high in most basal
tumors, but being infrequently expressed in most luminal breast tumors [18, 25, 39].
Therefore, it is likely that associations of Vimentin methylation with homogeneously low
Vimentin protein previously reported in luminal tumors would not have attained significance
in this dataset, given the heterogeneous methylation seen in our luminal A, luminal B, and
HER2-enriched tumors (Fig. 3a–c). Specifically, we suggest that the frequent Vimentin
methylation seen in luminal, but not in basal-like tumors, is part of a larger phenotype.
Indeed, future studies may show that Vimentin methylation is predictive of survival only in
luminal and/or HER2-enriched subtypes: breast tumors which contrast sharply with basal-
like tumors possessing their own distinct molecular signatures and biological origins [26, 27,
29, 34, 35]. For example, the majority of basal-like tumors are ER− by IHC, and we found
that Vimentin methylation predicted OS in ER+ but not ER− tumors (Fig. 4e, f). However,
differences in survival observed in Vimentin hypermethylated versus hypomethylated
(greater vs <20 % average methylation, respectively) ER− tumors may not have attained
statistical significance because of the smaller number of ER− tumors in our sample set.
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Therefore, future studies will interrogate a larger sample of ER− tumors to determine if
Vimentin methylation is a useful biomarker in predicting survival in these breast cancers.
Perhaps the most compelling explanation for Vimentin methylation predicting poor survival
may be ascribed to the previously described role of “drivers” in mediating deterministic and
predictable genetic and epigenetic changes in multiple downstream “passengers” [5, 40, 42].
In such a scenario, Vimentin methylation may be a passenger event resulting from non-
random epigenetic changes, and therefore may function as a reliable surrogate of a pathway
that is deterministic for poor survival. Previous studies support such a possibility in that
numerous gene promoters can be highly methylated without apparent effects on gene
expression at either the RNA or protein level [30, 40, 43].
The potential for selection bias is a concern for any tumor marker study [19]. However,
apart from the higher survival rates in the subset of basal-like tumors (Table 2, bivariate
analysis), OS characteristics of our sample were similar to previous breast cancer studies. In
order to address potential bias, we therefore excluded basal-like tumors in a subset of
survival analyses (Fig. 4c, d) and still obtained significant findings. As expected, other
variables previously known to confer poor survival, such as tumor size, stage, luminal B
subtype, nodal status, and metastatic disease, were significant in the bivariate analyses
(Table 2). Several strengths of our study are that (1) we quantified methylation for
individual CpG sequences spanning approximately 300 bp, (2) we assayed methylation in
luminal versus basal-like breast cell lines and then validated our findings in breast tumors,
(3) we tested Vimentin methylation in a bivariate model and also in a multivariate model
side by side with other strong predictors of survival, and (4) we carefully assayed matched
tumor-normal pairs (e.g., histologically normal ipsilateral breast tissues from cases), which
in turn allowed us to set relevant Vimentin methylation thresholds for our statistical
analyses.
In summary, regardless of whether it is a surrogate, or has a more direct biological role in
survival, the clinical implications of Vimentin methylation as a prognostic marker are great.
It is especially encouraging that the strength of the methylation effect on survival remained
robust in a multivariate model, even after including such strong predictors as nodal status
and metastatic disease at diagnosis. Future studies will determine the sensitivity and
specificity of Vimentin methylation to predict recurrence free and OS in both ER+ and ER−
tumors in a larger population-based study of breast cancer.
Additional material
Supplemental File 1 contains the geo names, and clinical and histopathological data for the
breast cancer cases. Supplemental File 2 provides methylation data for all the breast tumor/
matched normal pairs. Supplemental File 3 has Vimentin and GAPDH methylation in
positive and negative controls and breast cell lines. Supplemental File 4 details the bivariate
and multivariate analyses and Cox proportional hazards modeling.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Position of CpG dinucleotides interrogated for methylation. Top Row Base pair positions for
the Vimentin amplicon and CG dinucleotides are listed relative to the ATG translational
start site (TSS). The TATA box in the Vimentin promoter is at −192 bp. Bottom row
Expanded view of the 282-bp amplicon shows each of the 1–17 CG sequences (represented
by a circle on top of a vertical line), interrogated for methylation relative to the TSS. The
entire sequence was based on human build NCBI 36/hg19, with the Vimentin amplicon
spanning bp 17311015–17311296
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a Cluster analysis of differential Vimentin methylation in breast cancer cell lines. Vimentin
DNA methylation was quantified on a mass array platform per CpG unit across the
amplicon. Percent methylation is represented on a color continuum from zero percent
methylation (gold) to 50 % methylation (black) to 100 % methylation (purple). ER+ and
HER2+ luminal cell lines (T47D, MCF7, ZR75 and SKBR3) were hypermethylated while
the remaining hormone receptor (HR−) cell lines were hypomethylated. b Vimentin qRT-
PCR electrophoresis in breast cancer cell lines. qRT-PCR was carried out in a subset of
breast cell lines on an ABI 7500 real-time platform in 20 µl reaction volumes. GAPDH was
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amplified in tandem and used as the reference control. Vimentin product bands (73 bp) are
faint or absent for the luminal, hypermethylated cell lines (lanes 1–4), while robust product
bands are seen in the HR− cell lines (lanes 5–11). c Vimentin expression in breast cancer
cell lines. qRT-PCR was used to quantify Vimentin expression relative to GAPDH using
commercially available ABI TaqMan probes and primers. All breast cell lines were
examined in triplicate. Error bars represent the standard error of the mean. HCC1937 was
used as the referent cell line, and log10 (RQ) was set at 3.5. Differences between luminal and
HR− cell line mRNA expression were highly significant by the student’s t test (t = 10.12; p
< 0.00001) and by the Mann–Whitney test (U = 32.0; p < .01)
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a, b Vimentin methylation in breast tumors and matched tumor normal pairs by molecular
subtype. a Breast tumors (n = 81) are listed on the horizontal axis and percent methylation
on the vertical axis. Diamonds represent percent methylation for each CpG unit within the
Vimentin amplicon. Note Similar percent methylation values for either CpGs 1, 2, 3, 4, 5, 6,
7, 8, 16, and 17 can overlap and may appear as “one diamond.” Tumors are grouped by
molecular subtypes assigned from previous oligoarray analysis. (Basal = red, HER2-
enriched = pink, Luminal A = Dark Blue, and Luminal B = Light blue). b Top row
Methylation of n = 57 tumors and n = 57 matched adjacent normal breast tissue pairs.
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Differential methylation is seen in tumors, while paired normal tissues have average baseline
methylation values of 11 % or less. c ANOVA of Vimentin CpG 17 methylation by
molecular subtype. ANOVA was performed in n = 83 tumors + N = 57 matched normal
pairs (n = 140 total samples) and grouped by molecular subtype (x axis). The boxplot shows
percent methylation distributions where the upper and lower whiskers represent 1.5 times
the interquartile range (IQR). Significant differences (p < 0.00001) were observed in percent
methylation between tumor subtypes
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a–f Overall and recurrence free survival by Vimentin methylation status. Kaplan–Meier
overall (OS) and recurrence free (RFS) survival analyses were carried out by stratifying
breast cancer patients with average Vimentin methylation thresholds above 20 percent (1 =
red line) and below 20 percent (0 = blue line) based on relative methylation in matched
normal tissues. OS and RFS were recorded in months (horizontal axis). The number of
tumors in each analysis varied according to complete data available for the variables under
study: a OS in N = 79 breast tumors, b RFS in N = 65 breast tumors, c OS in N = 58 tumors
after removing the basal-like tumors from the analysis, d RFS in N = 51 tumors after
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removing 22 basal-like tumors from the analysis, e OS in N = 47 ER+ tumors only, f OS in
N = 32 ER− tumors only. Results for Fig. 4a–e were highly significant and showed breast
cancer patients with <20 % average Vimentin methylation survive much longer than those
with >20 % methylation (range log rank χ2 = 5.93–7.51, p = 0.015–0.006). Survival
differences were not significant in ER− breast tumors (f)
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Table 1
Gene expression versus Vimentin methylation in tumors








Pearson correlation coefficients were calculated based on log2 expression values from oligo DNA microarray (Agilent) Vimentin probe P161190
with percent methylation values for CpG units 1–17. Methylation was significantly inversely correlated with Vimentin expression, with coefficients
ranging from −0.228 to −0.381 (p = 0.019–0.001). Results are based on n = 76 tumors for which there were both complete methylation and
oligoarray data
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Table 2







Methylation >20 % 0.012 79 0.019 0.011
Lymph Node Status <0.001 79 0.005 0.004
Metastatic Disease <0.001 80 0.001 <0.001
Female 0.015 80 0.043
Black 0.122 77
Age 0.212 80
ER Positive 0.588 80
HER2 Positive 0.593 73
Molecular Subtype 78
  Luminal A –
  Basal 0.973
  Luminal B 0.054
  HER2 Over-expressing 0.990
Tumor Size 80
  <=2 cm –
  2–5 cm 0.024
  >5 cm 0.004
Tumor Stage 80
  Stage 1 –
  Stage II 0 058
  Stage III 0.005
  Stage IV 0.001
Parameter Hazard ratio 95 % Confidence intervals***
Lower limit Upper limit
Methylation >20 % 2.6 1.2 5.3
Lymph node positivity 3.1 1.4 6.6
Metastatic disease 4.3 1.9 9.7
Bivariate analysis identified marginally significant (p < 0.1) predictors of survival later tested in multivariate Cox regression models. Reference
categories were set for those predictors with more than two categories (Supplemental file 3)
Possible predictors in the multivariate model were used to generate composite models through forward, backward, and stepwise selection, with p =
0.05 as the basis for removing and retaining variables. All three approaches generated the same model with multivariate model
*
1A based on N = 75 female and N = 3 male (total N = 78 cases), and multivariate model
**
1B based on N = 75 female-only breast cancer cases
***
Hazard ratios were based on multivariate model 1B and show women with >20 % average Vimentin methylation were 2.6 times more likely to
die compared to those with lower Vimentin methylation levels
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